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Background: Early diagnosis of SARS-CoV-2 infection is essential to reduce disease spread. Rapid antigen tests
have not been sufficiently evaluated in asymptomatic patients to be used as massive population screening
tools.
Methods: Head-to-head evaluation of Roche SARS-CoV-2 Rapid Antigen Test and real-time reverse transcrip-
tion polymerase chain reaction (RT-PCR) as SARS-CoV-2 screening tools performed in asymptomatic adults
from a semi-closed community in University of Navarra (Spain) from November 2020 to January 2021. Sensi-
tivity, specificity and predictive values were calculated using RT-PCR as reference method.
Findings: Roche SARS-CoV-2 Rapid Antigen Test was performed on 2542 asymptomatic adults in a commu-
nity with a SARS-CoV-2 incidence of 1¢93%. It showed a sensitivity of 71¢43% (CI 95%: 56¢74  83¢42) and a
specificity of 99¢68% (CI 95%: 99¢37 - 99¢86). Positive Predictive Value was 81¢4 (CI 95% 66¢6  91¢61) and
Negative Predictive Value was 99¢44 (CI 95% 99¢06  99¢69). Test sensitivity was related to viral load, with
higher sensitivity in RT-PCR cycle threshold (Ct) values under 25 (93¢75%, CI 95%: 71¢96  98¢93), that
dropped to 29¢41% (CI 95%: 10¢31- 55¢96) in RT-PCR Ct values above 25.
Interpretation: This study suggests that rapid antigen tests are less effective in asymptomatic population,
when compared with RT-PCR. Further studies are needed to evaluate different options to improve screenings
based on rapid antigen test, such as the use of clinical questionnaires to select higher risk-participants, the
confirmation of negative results with RT-PCR or the use of repetitive sequential testing.
Funding: This research received no external funding.
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The search for rapid, accurate and affordable Severe Acute Respi-
ratory Syndrome Coronavirus 2 (SARS-CoV-2) diagnosis tools has
become a global priority during Coronavirus-related Disease (COVID-
19) pandemic. Effective tests useful for widespread testing andcontact tracing are essential in public health policies to control
COVID-19 [13].
The real-time reverse transcription polymerase chain reaction
(RT-PCR) obtained from nasopharyngeal or oropharyngeal swab sam-
ples is currently the most used diagnosing-test and it is considered
the gold standard specimen for SARS-CoV-2 RNA testing [46]. It is a
very sensitive method and when used quantitatively, analyzing the
cycle threshold (Ct), it also gives information on the viral load and
the infectiousness [7]. However, sometimes its use is limited, as it
requires long turnaround times, skillful operators, biosafety meas-
ures, expensive instrumentation and a laboratory setting, resources
not always available in most geographical areas.
Research in context
Evidence before this study
The pandemic caused by the Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) is causing severe health, social and
economic problems worldwide. The search for rapid, accurate and
affordable SARS-CoV-2 diagnosis tools has become a global priority.
The real-time reverse transcription polymerase chain reaction (RT-
PCR) is a very sensitive method but Rapid diagnosis tests, based on
antigen detection are faster, easier to perform and cheaper. There
is scarce evidence on the accuracy of these tests inwidespread test-
ing of asymptomatic populations in different settings. Kr€uttgen et
al and Lefever et al in 2021 have performed some previous valida-
tion study, but in smaller samples or including symptomatic
patients.
Added value of this study
It is urgent to validate SARS-CoV-2 rapid antigen tests for wide-
spread SARS-CoV-2 testing, for the diagnosis of SAR-CoV-2 infec-
tion in asymptomatic patients. Our results with Roche rapid
antigen test on 2542 asymptomatic adults showed a sensitivity of
71¢43% (CI 95%¢ 56¢74  83¢42) and a specificity of 99¢68% (CI 95%:
99¢37  99¢86). Test sensitivity was related to viral load, with
higher sensitivity in RT-PCR Ct values under 25.
Implications of all the available evidence
This study demonstrates that rapid antigen tests are less effective
in asymptomatic population. Further strategies such as periodic
sampling or repeated measures might increase the test efficacy
and should therefore be evaluated.
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to perform and cheaper. They can be used outside the laboratory and
with fast turnaround times, therefore they could be essential when
implementing population policies. These rapid tests, through a rapid
chromatographic immunoassay technique, are used for the qualita-
tive detection of SARS-CoV-2 antigens generally in nasopharyngeal
swabs, they can be easily interpreted without specialized instrument
and in less than 30 min. Most rapid antigen test have been designed
and validated for the detection of SARS-CoV-2 in patients with
COVID-19 symptoms in hospital settings, and there is currently little
evidence on the accuracy of these tests in widespread testing of
asymptomatic populations and in different settings [8].
According to the WHO, these rapid test need to be better evalu-
ated and they are currently not recommended for clinical diagnosis
[9]. As recently published by Boehme et al. generalized testing, out-
side a health-care setting, depends on factors related to the test, such
as test-sensitivity, sampling method, turnaround-time and costs, and
on factors related to the setting or community where the test will be
used, such as level of exposure, contact patterns, local prevalence and
type of community [1]. During the COVID19 pandemic, public health
policies aiming at keeping the regular activity in semi-closed commu-
nities, like workplaces, schools or universities, are based on general
measures, such as social distancing, mask wearing and basic hygienic
measures, but a proactive broad population surveillance to stop
asymptomatic spread and prevent outbreaks is also advisable and
has been implemented in many regions. Nevertheless, head-to-head
comparisons of available SARS-CoV-2 rapid antigen detection tests
are scarce, with limited sample-size and wide range of clinical set-
tings showing irregular test-performance between different studies
and different brands [10,11].
The objective of this study was to validate a SARS-CoV-2 rapid
antigen test for widespread SARS-CoV-2 testing in a semi-closedcommunity. We present the results of a single-center cross-sectional
head-to-head validation study of Roche SARS-CoV-2 Rapid Antigen
Test for the diagnosis of SAR-CoV-2 infection in asymptomatic adults




Study performed within the COVID-19 transmission prevention
plan of the University of Navarra (Pamplona, Spain) where massive
randomized SARS-CoV-2 PCR tests are periodically performed. The
present study was carried out according to STARD guidelines among
randomly selected university students and employees. Inclusion in
the study was voluntary and informed consent was signed prior to
inclusion. Out of the 16,869 potentially eligible participants (current
staff and students from the University of Navarra), 2543 were
included in this study after being scheduled for a randomized mass
testing between November 2020 and January 2021, as shown in
Fig. 1. The only exclusion criterion was the presence of COVID-19
symptoms (fever, persistent cough, or shortness of breath). Patients
with nonspecific mild symptoms (such as nasal congestion, odyno-
phagia, isolated headache or isolated gastrointestinal symptoms) and
COVID-19 close-contacts (individuals who had been in contact with a
Covid-19 positive patient without adequate protection measures,
closer than 2 m and for longer than 15 min, 48 h before symptoms
onset or diagnosis of the Covid-19 patient) were not excluded.
2.2. SARS-CoV-2 testing
Nasopharyngeal and oropharyngeal swabs samples were obtained
from each participant by a trained nurse on the same visit. The rapid
antigen test and the RT-PCR for SARS-CoV-2 detection, were simulta-
neously performed.
Roche SARS-CoV-2 Rapid Antigen Test is a rapid chromatographic
immunoassay intended for the qualitative detection of specific anti-
gens of SARS‑CoV‑2 present in human nasopharynx. It detects the
SARS-CoV-2 nucleoprotein, and it can be used to assess whether a
person is infected with SARS-CoV-2 by providing a qualitative result
shown as colored bands. In addition, the SARS-CoV-2 Rapid Antigen
Test does not use any laboratory instruments that automate the pro-
cess, it is therefore easy to use, and it does not require specific train-
ing. The detailed test protocol as well as the validation results
(sensitivity 96.52% and specificity 99.68%) in hospital setting can be
found on the manufacturer's website [12]. The rapid antigen test was
performed by trained personnel on nasopharyngeal samples on site,
following the manufacturer's instructions. Two technicians per-
formed two independent blind readings. When a disparity between
readings appeared (0.32%), a third technician broke the tie.
RT-PCR was carried out in the Genomic Unit of the Center for
Applied Medical Research (CIMA) at the University of Navarra. Sam-
ples were obtained by oropharyngeal swabbing and placed in a poly-
propylene tube with 500 ml of lysis solution (RLT Plus, Qiagen).
Samples were then transferred from the tubes to a 96-well plate
using a Tecan Freedom EVO 150 robotic system. RNA extraction was
carried out according to the protocol developed by CIMA researchers
[13] using superparamagnetic particles (Dynabeads MyOne SILANE,
Thermofisher), adapted for automation on an Agilent Bravo NGS sys-
tem. Briefly, the samples were mixed with the magnetic particles and
ethanol, so that the particles capture the RNA [14]. The magnetic par-
ticles are then immobilized with a magnet, washed twice with 80%
ethanol and nucleic acids are eluted in 10 mM Tris, pH 7. The “Real-
time fluorescent RT-PCR kit for detecting 2019-nCoV” (BGI ref.
HW4412) was used for the detection of coronavirus RNA by reverse
transcription quantitative PCR (RT-qPCR) in a thermal cycler
Fig. 1. Study Flow-chart: Validation of a rapid antigen test as a screening tool for SARS-CoV-2 infection in asymptomatic populations.
* Fever, persistent cough, or shortness of breath.
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QuantStudio Design Analysis Software (Thermofisher). This process
has been validated by the Spanish Carlos III Health Institute in April
2020.
Samples for RT-PCR analysis were transferred to the laboratory in
the next 5 h after collection. Samples were stored at local room tem-
perature. The CIMA analyzed and reported the results on the same
day the sample was collected. The results of both tests were indepen-
dently introduced into independent databases, anonymized and
merged into a single database for analysis.
2.3. Statistical analysis
Sensitivity, specificity, negative predictive value (NPV) and posi-
tive predictive value (PPV) with their respective 95% confidence
intervals (CI) using binomial or Agresti and Coull methods. Analyses
were performed on the total sample and splitting the population into
two categories: “asymptomatic low-risk participants” and “partici-
pants at increased risk of SARS-CoV-2 infection” (including COVID-19
close contacts and those who reported non-specific mild symptoms).
Kappa index was used to study tests correlation.
Based on previous studies and in order to be able to compare
our results with previous findings, the positive RT-PCR test
results have been categorized and analyzed according to their
quantitative Ct-value in two different ways. First using the Ct-val-
ues divided into four intervals (<20, 20 to <25, 25 to <30, and
30 Ct) and later using four accumulative categories (<20, <25,
<30 and <35). Rapid antigen test sensitivity was calculated
across Ct threshold categories.
A bee swarm style graphic representation of the positive RT-PCR
tests according to their Ct-value and divided into two groups depend-
ing on whether the rapid antigen test had been positive or negative
was also performed. On this graph the median Ct value is represented
by the middle line in each swarm while the upper and lower linesrepresent the interquartile range (p75 and p25). A Mann-Whitney U
test was performed to compare the differences among groups. Analy-
ses were performed using STATA 12.0.
Sample size estimation was determined considering a power of
0¢90, a type I error of 0¢05 and a SARS-CoV-2 prevalence of 1¢3%. Sen-
sitivity values and specificity of 96¢52 and 99¢68 respectively were
assumed as previously reported in clinical setting.[12] The estimated
sample size for rejecting the null hypothesis of non-inferiority to PCR
testing was 760 participants. Missing data and dropout rate were
zero, recruitment coincided with the first and only visit and all ran-
domly selected participants accepted to enter the study.
Roche Diagnostics International Ltd. provided the rapid antigen
tests required for the study. A contract was signed with Roche Diag-
nostics International Ltd. including our commitment to perform the
test according to their protocols and defining the role of the funding
source. The contract specified that Roche will not be involved in the
study-design, data-analysis nor in the interpretation of results or in
the decision to publication, and that Roche will have access to the
study results, but not to the study data. The study was conducted in
compliance to the study protocol, the current version of the Declara-
tion of Helsinki, and the local, legal and regulatory requirements
(Approved by the University of Navarra Ethics committee: 2020.216
on October 30th, 2020). An informed consent was given to all partici-
pants and singed by both parties.2.4. Role of the funding source
This research received no external funding. Roche Diagnostics
International Ltd. donated the rapid antigen tests required for the
study, but had no role in data collection, analysis, generation of
results or decision to submit for publication. Dr. Fernandez-Montero,
Prof. Ari~no and Dr. Moreno-Galarraga had access to the full dataset
and took the decision to submit the manuscript for publication.
Table 1
Baseline characteristics of participants according to risk of SARS-CoV-2 infection.
Asymptomatic Higher COVID-19 risk* p
N 2288 255
Sex, women N (%) 1392 (62¢06) 165(65¢74) 0.254
Age, mean (Standard
deviation)
28¢06 (12¢32) 23¢63 (7¢1) <0.001
*Including participant with non-specific mild symptoms and close contacts.
Table 3
Sensitivity of the SARS-CoV-2 Rapid Antigen Test according to
RT-PCR Ct intervals.
Ct values N True positive Sensitivity% (CI95%)
<20 9 9 100 (65¢54100)*
20 - <25 23 21 91¢30 (71¢9698¢93)
25 - <30 9 4 44¢44 (13¢778¢8)
30 8 1 12¢5 (0¢3252¢65)
* calculate Agresti-Coull confidence intervals.
Table 4
Sensitivity of the SARS-CoV-2 Rapid Antigen Test according to
RT-PCR Ct accumulative categories.
Ct values N True positive Sensitivity% (CI95%)
<20 9 9 100 (65¢54100)*
<25 32 30 93¢75 (79¢1999¢23)
<30 41 34 82¢93 (67¢9492¢85)
<35 48 35 72¢92 (58¢1584¢72)
* calculate Agresti-Coull confidence intervals.
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Out of 2543 participants (62¢4% females, mean age 27¢61 § 11¢97-
year-old), 49 cases of SARS-CoV-2 infection were RT-PCR confirmed
during the study period. Sample description is showed in Table 1.
Total SARS-CoV-2 incidence was 1¢93%. The study sample was mainly
composed of asymptomatic participants (90%) among whom COVID-
19 incidence was 0¢66%. The rest of participants were considered as
higher COVID-19 risk participants, and this group included close
COVID-19 contacts (9%) with a 12¢72% incidence, and mild-symptom-
atic participants (1%) with a 18¢52% incidence of COVID-19. No
adverse events were detected during the procedures.
The rapid SARS-CoV-2 antigen test showed in the total sample
low sensitivity (71¢43%), moderate PPV (81¢40%), high specificity
(99¢68%) and high NPV (99¢44%) (Table 2) with a moderate agree-
ment (kappa index=0¢76) between the two tests. When the sam-
ple was divided into asymptomatic-low-risk and high-risk
participants, the rapid SARS-CoV-2 antigen test presented lower
sensitivity (53¢33%) and PPV (53¢33%) values and higher specific-
ity (99¢69%) and NPV (99¢69%) in asymptomatic participants, and
moderate amounts of sensitivity (79¢41%), high specificity
(99¢55%), PPV (96¢43%) and NPV (96¢91%) in patients with higher
COVID-19 risk (Table 2).
Table 3 shows how the rapid SARS-CoV-2 antigen test has a high
capacity to detect positives in samples with higher viral loads (Sensi-
tivity of 93¢75% (CI 95% 79¢1999¢23) in RT-PCR Ct values below 25)
but a lower capacity to detect infection in samples with lower viral
load (Sensitivity of 29¢41% (CI 95% 10¢3155¢96) in RT-PCR Ct values
above 25). When analyzing the results dividing the sample in four
accumulative categories, sensitivity ranged from 100% in Ct<20 to
72¢92% in Ct<35. A decline in the test performance was observed as
the Ct values increased (Table 4).
Fig. 2 shows significant difference in the Ct values when compar-
ing the group with positive RT-PCR and negative Rapid Antigen Test
(median Ct values 29¢95 interquartile range 28¢0732¢05) with the
group with positive RT-PCR and positive Rapid Antigen Test (median
Ct values 22¢3 interquartile range 19¢9124¢42) (p <0¢001).
4. Discussion
This observational study, designed to analyze the efficacy of the
Roche SARS-CoV-2 Rapid Antigen Test, showed the limitations of this
test when used as a screening massive tool for the diagnosis of acute
SARS-CoV2 infection in asymptomatic populations.Table 2
Validation result of SARS-CoV-2 Rapid Antigen Test compare
Asymptomatic
N 2288
Cases (incidence) 15 (0¢66)
Sensitivity% (IC95%) 53¢33 (26¢5978¢73
Specificity% (IC95%) 99¢69 (99¢3799¢88
Positive predictive value% (CI95%) 53¢33 (26¢5978¢73
Negative predictive value% (CI95%) 99¢69 (99¢3799¢88
*Including participant with non-specific mild symptoms andIt is urgent to validate the new rapid diagnostic techniques to
detect SARS-CoV2 infection status in different clinical settings and in
different populations. Screening programs are essential in public
health strategies and massive testing is essential as social distancing,
lock downs and home confinement cannot be long term measures.
Tests used in these screening programs should be validated in differ-
ent settings and conditions, to optimize the available test according
to each context. The purpose of this study was to validate a rapid
antigen test as a screening tool in a semi-closed community, (Univer-
sity community) in a pandemic situation (incidence 1¢93%) evaluating
its suitability for diagnosing acute infection in asymptomatic adults.
When used on symptomatic patients Roche SARS-CoV-2 rapid anti-
gen test has proven to have high sensitivity and specificity [12],
meeting WHO recommended criteria of 80% sensitivity and 97%
specificity. The results of the Roche-rapid test on this low-prevalent
population when compared with RT-PCR test showed a sensitivity of
71¢43% and a specificity of 99¢68% with a moderate concordance
between both tests (k = 0¢76). These results were comparable to those
recently obtained in studies based on rapid antigen detection tests, in
mixed populations including both symptomatic and asymptomatic
individuals [11,15]. We found, as previously published [15,16], that
rapid antigen test sensitivity was related to viral load, showing better
results in samples with lower RT-PCR Ct values. Kr€uttgen et al. calcu-
lated that the Roche SARS-CoV-2 Rapid Antigen Test sensitivity was
100% in samples with a high viral load (Ct < 25) but that the test sen-
sitivity dropped to 95%, 44¢8%, and 22¢2% in samples with medium
(Ct 25-<30), low (Ct 30-<35) and very low (Ct >35) viral loads,
respectively [16]. Lefever et al. [17] also validated a rapid-test
although in their study they used an automated reading test per-
formed in a laboratory (DiaSorin Liaison antigen test) and used a dif-
ferent genetic target in the RT-PCR test (N1 and N2 region of the
nucleocapsid phosphoprotein gene), despite these differences this
study showed almost identical results. We performed additionald to RT-PCR test.
Higher COVID-19 risk* Total sample
255 2543
34(13¢33) 49 (1¢93)
) 79¢41 (62¢1091¢30) 71¢43 (56¢7483¢42)
) 99¢55 (97¢5099¢99) 99¢68 (99¢3799¢86)
) 96¢43 (81¢6599¢91) 81¢40 (66¢6091¢61)
) 96¢91 (93¢7498¢75) 99¢44 (99¢0699¢69)
close contacts.
Fig. 2. Graphical representation of positive and negative antigen results according to
RT-PCR Ct values. Validation study of a rapid antigen test as a screening tool for SARS-
CoV-2 infection.
RT-PCR: Real-time reverse transcription polymerase chain reaction; Ct: cycle
threshold.
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gories as performed in the work published by Lefever et al. When
using the same CT cut-off threshold in our study, (cut-off points of
<20, <25, <30 and <35), we appreciate a sensitivity of 100%, 93¢8%,
82¢9% and 72¢92% respectively, very similar to the data published by
Lefever et al. showing a sensitivity of 100%, 94¢8%, 83¢2% and 71¢3%.
Both studies show how regardless the type of antigen test used, the
automation of the process, or the genetic target used in the RT-PCR
test, rapid antigen tests decrease their sensitivity to detect SARS-
CoV-2 as viral load decreases.
As it is not possible to differentiate whether low viral loads are
residual viral loads (reflecting the last stage of the disease) or they
represent a very early stage of the disease, the false negatives of this
study could leave undetected some SARS-CoV2 individuals during
the incubation period. This could have dangerous consequences due
to a false safety impression on a patient entering a high contagious
phase. As samples obtained on the first days after symptoms onset
are most likely to contain[18] higher viral loads, this finding is con-
cordant to the current WHO guidelines [19], that recommends that
rapid antigen test should be used only in symptomatic cases (24 h
after symptoms on-set) and within the first 57 days of the onset of
symptoms. Being currently crucial to detect asymptomatic early
SARS-CoV2 infected subjects, the false-negative antigen tests seen in
this cohort (28,57%) acquire important public health consequences,
as not detecting potentially contagious patients could dangerously
increase the infection spread. Roche SARS-CoV-2 Rapid Antigen Test
performance has proven to be excellent in nasopharyngeal swabs
from symptomatic patients with low Ct values, but according to the
data here presented, it seems to be insufficient for massive screening
of asymptomatic population.
The test accuracy on asymptomatic population, might question
the value of the rapid antigen test as screening diagnostic tools. Nev-
ertheless, the rapid tests do have an important value when posi-
tioned appropriately and they can be useful and efficient tools when
used correctly. In a pandemic situation, when a cheap, rapid and
widely distributed test may be needed, different options such as
using clinical questionnaires to select higher risk patients, the used of
repetitive sequential measures [20], or the use of rapid antigen test
as an initial screening, understanding that negative results will need
to be confirmed by RT-PCR test, will increase the test sensibility.
Therefore, rapid antigen tests could be an efficient policy if used cor-
rectly. More studies are needed in order to confirm these results andthe efficacy and effectivity of repeated testing [21]. In a high preva-
lence situation, a positive rapid antigen test has a high positive pre-
dictive value, whereas negative results should never be used to
decrease the standard protective measures.
Our study has some limitations that should be addressed. Sample
size calculation was done with an assumption of a 90% sensitivity
based on the manufacturer's information, so the final statistical
power was lower than expected. Still, the sample size is large and it
triples the required sample size. Viral culture was not performed, so
the real relationship between positive rapid antigen test and con-
tagiousness remains unclear. Only RT-PCR Ct values were measured,
and although there is significant variation in Ct values depending on
the region of the target gene used, they have been related to viral
load [22], and furthermore, the results of our study are similar to
other studies even when using different target genes [16,17].
Also, when designing validation studies, biological, immunologic,
technical and temporal aspects are important to consider. The
samples used were performed by the same technician and in the
same visit, but one test was performed on oropharyngeal swabs
while the other was performed on nasopharyngeal swaps which
could have led to different RNA concentrations due to different
RNA shedding at the two sites. We used the samples required
according to each test protocol, but as new screening test are
developed, using different samples (nasopharyngeal, oropharyn-
geal, rectal or saliva) and different collection methods (provider-
vs. patient-collected samples) deserve further study. The evidence
regarding different RNA concentrations in different samples and
different phase of the infection cycle needs to be better
addressed. Finally, another study limitation was the difficulty to
differentiate if the low viral-loads undetected by the rapid anti-
gen test (false negatives) represent the initial or the late stage of
the disease. If they represent an early moment in the SARS-CoV-2
infection, not detecting these individuals will be a high-risk
action, especially if they wrongly get a false feeling of security.
On the other hand, if these undetected low viral loads represent
a late stage of the disease, individuals will probably be non-infec-
tive, or become non-infective soon, and therefore this false nega-
tive will not be such a potential theat. We believe further studies,
including clinical follow-up and repeated diagnostic test will be
key to better understand this situation.
In conclusion, the Roche SARS-CoV-2 Rapid Antigen Test showed a
moderate sensitivity on asymptomatic patients, when compared with
RT-PCR. Test sensitivity and specificity increased in patients with
higher viral loads or higher COVID-19 risk (presence of mild symp-
toms or known exposure to SARS-CoV-2) but it was lower in asymp-
tomatic low risk patients, with an overall 28¢57% of false negatives.
The Roche SARS-CoV-2 Rapid Antigen Test is not a useful tool to
be used as a single screening test in semi-closed low risk communi-
ties. Further strategies such as periodic sampling or repeated meas-
ures might increase the test efficacy and should therefore be
evaluated.
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